IMPA1 is essential for embryonic development and lithium-like pilocarpine sensitivity

Neuropsychopharmacology

Volumn 33, Issue 3, 2008, Pages 674-684

  Cryns, Kim ^a   Shamir, Alon ^b   Van Acker, Nathalie ^c   Levi, Itzhak ^b   Daneels, Guy ^a   Goris, Ilse ^a   Bouwknecht, J Adriaan ^a   Andries, Luc ^c   Kass, Stefan ^a   Agam, Galila ^b   Belmaker, Haim ^b   Bersudsky, Yuly ^b   Steckler, Thomas ^a   Moechars, Dieder ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c HistoGeneX NV   (Belgium)

Author keywords

Bipolar disorder; IMPA1; IMPase activity; Inositol; Lithium; Pilocarpine

Indexed keywords

INOSITOL 1 PHOSPHATASE; LITHIUM CARBONATE; PILOCARPINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DRUG SENSITIVITY; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; FEMALE; FORCED SWIMMING TEST; GENE FUNCTION; GENE TARGETING; HOMOZYGOSITY; IN VIVO STUDY; MALE; MOTOR ACTIVITY; NONHUMAN; OPEN FIELD TEST; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; ANTIMANIC AGENTS; BEHAVIOR, ANIMAL; BODY WEIGHT; CHROMATOGRAPHY, GAS; DRINKING; EMBRYONIC DEVELOPMENT; INOSITOL; LITHIUM CARBONATE; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; MUSCARINIC AGONISTS; MUTAGENESIS; PHOSPHORIC MONOESTER HYDROLASES; PILOCARPINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SWIMMING;

EID: 38149044120     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301431     Document Type: Article

References (43)

1. Agam G, Shamir A, Shaltiel G, Greenberg ML (2002). Myo-inositol-1- phosphate (MIP) synthase: a possible new target for antibipolar drugs. Bipolar Disord 4: 15-20.
2. Allison JH, Blisner ME, Holland WH, Hipps PP, Sherman WR (1976). Increased brain myo-inositol l-phosphate in lithium-treated rats. Biochem Biophys Res Commun 71: 664-670.
3. Allison JH, Stewart MA (1971). Reduced brain inositol in lithium-treated rats. Nat New Biol 233: 267-268.
4. Atack JR, Broughton HB, Pollack SJ (1995). Inositol monophosphatase-a putative target for Li+ in the treatment of bipolar disorder. Trends Neurosci 18: 343-349.
5. Batty IH, Downes CP (1994). The inhibition of phosphoinositide synthesis and muscarinic-receptor-mediated phospholipase C activity by Li+ as secondary, selective, consequences of inositol depletion in 1321N1 cells. Biochem J 297(Pt 3): 529-537.
6. Berrettini WH, Ferraro TN, Goldin LR, Weeks DE, Detera-Wadleigh S, Nurnberger Jr JI et al (1994). Chromosome 18 DNA markers and manic-depressive illness: evidence for a susceptibility gene. Proc Natl Acad Sci USA 91: 5918-5921.
7. Berridge MJ, Downes CP, Hanley MR (1982). Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J 206: 587-595.
8. Berridge MJ, Downes CP, Hanley MR (1989). Neural and developmental actions of lithium: a unifying hypothesis. Cell 59: 411-419.
9. Berridge MJ, Irvine RF (1989). Inositol phosphates and cell signalling. Nature 341: 197-205.
10. Bersudsky Y, Kaplan Z, Shapiro Y, Agam G, Kofman O, Belmaker RH (1994). Behavioral evidence for the existence of two pools of cellular inositol. Eur Neuropsychopharmacol 4: 463-467.
11. Bone R, Frank L, Springer JP, Pollack SJ, Osborne SA, Atack JR et al (1994). Structural analysis of inositol monophosphatase complexes with substrates. Biochemistry 33: 9460-9467.
12. Brand A, Richter-Landsberg C, Leibfritz D (1993). Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 15: 289-298.
13. Chau JF, Lee MK, Law JW, Chung SK, Chung SS (2005). Sodium/myo-inositol cotransporter-1 is essential for the development and function of the peripheral nerves. FASEB J 19: 1887-1889.
14. Cryns K, Shamir A, Shapiro J, Daneels G, Goris I, Van Craenendonck H et al (2007). Lack of lithium-like behavioral and molecular effects in IMPA2 knockout mice. Neuropsychopharmacology 32: 881-891.
15. Di Daniel E, Cheng L, Maycox PR, Mudge AW (2006). The common inositol-reversible effect of mood stabilizers on neurons does not involve GSK3 inhibition, myo-inositol-1-phosphate synthase or the sodium-dependent myo-inositol transporters. Mol Cell Neurosci 32: 27-36.
16. Einat H, Manji HK, Belmaker RH (2003). New approaches to modeling bipolar disorder. Psychopharmacol Bull 37: 47-63.
17. Fisher SK, Novak JE, Agranoff BW (2002). Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J Neurochem 82: 736-754.
18. Frey R, Metzler D, Fischer P, Heiden A, Scharfetter J, Moser E et al (1998). Myo-inositol in depressive and healthy subjects determined by frontal 1H-magnetic resonance spectroscopy at 1.5 tesla. J Psychiatr Res 32: 411-420.
19. Ganzhorn AJ, Lepage P, Pelton PD, Strasser F, Vincendon P, Rondeau JM (1996). The contribution of lysine-36 to catalysis by human myo-inositol monophosphatase. Biochemistry 35: 10957-10966.
20. Goodwin FK, Jamison KR (1990). Manic-Depressive Illness. Oxford University Press: New York.
21. Hallcher LM, Sherman WR (1980). The effects of lithium ion and other agents on the activity of myo- inositol-1-phosphatase from bovine brain. J Biol Chem 255: 10896-10901.
22. Harwood AJ (2005). Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited. Mol Psychiatry 10: 117-126.
23. Honchar MP, Olney JW, Sherman WR (1983). Systemic cholinergic agents induce seizures and brain damage in lithium-treated rats. Science 220: 323-325.
24. Kofman O, Belmaker RH (1993). Ziskind-Somerfeld Research Award 1993. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression. Biol Psychiatry 34: 839-852.
25. Kofman O, Sherman WR, Katz V, Belmaker RH (1993). Restoration of brain myo-inositol levels in rats increases latency to lithium-pilocarpine seizures. Psychopharmacology (Berl) 110: 229-234.
26. Lubrich B, Patishi Y, Kofman O, Agam G, Berger M, Belmaker RH et al (1997). Lithium-induced inositol depletion in rat brain after chronic treatment is restricted to the hypothalamus. Mol Psychiatry 2: 407-412.
27. Novak JE, Agranoff BW, Fisher SK (2000a). Increased expression of Galpha(q/11) and of phospholipase-Cbeta1/4 in differentiated human NT2-N neurons: enhancement of phosphoinositide hydrolysis. J Neurochem 74: 2322-2330.
28. Novak JE, Agranoff BW, Fisher SK (2000b). Regulation of Myo-inositol homeostasis in differentiated human NT2-N neurons. Neurochem Res 25: 561-566.
29. Novak JE, Turner RS, Agranoff BW, Fisher SK (1999). Differentiated human NT2-N neurons possess a high intracellular content of myo-inositol. J Neurochem 72: 1431-1440.
30. O'Brien WT, Harper AD, Jove E, Woodgett JR, Maretto S, Piccolo S et al (2004). Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 24: 6791-6798.
31. Ohnishi T, Ohba H, Seo KC, Im J, Sato Y, Iwayama Y et al (2007). Spatial expression patterns and biochemical properties distinguish a second myo-inositol monophosphatase IMPA2 from IMPA1. J Biol Chem 282: 637-646.
32. Patel S, Meldrum BS, Fine A (1988). Susceptibility to pilocarpine-induced seizures in rats increases with age. Behav Brain Res 31: 165-167.
33. Rojas K, Liang L, Johnson EI, Berrettini WH, Overhauser J (2000). Identification of candidate genes for psychiatric disorders on 18p11. Mol Psychiatry 5: 389-395.
34. Shaldubina A, Johanson RA, O'Brien WT, Buccafusca R, Agam G, Belmaker RH et al (2006a). SMIT1 haploinsufficiency causes brain inositol deficiency without affecting lithium-sensitive behavior. Mol Genet Metab 88: 384-388.
35. Shaldubina A, Stahl Z, Furszpan M, Regenold WT, Shapiro J, Belmaker RH et al (2006b). Inositol deficiency diet and lithium effects. Bipolar Disord 8: 152-159.
36. Shamir A, Sjoholt G, Ebstein RP, Agam G, Steen V (2001). Characterization of genes encoding mouse myo-inositol monophosphatase (Impa1 and Impa2). Gene 271: 285-289.
37. Shapiro J, Belmaker RH, Biegon A, Seker A, Agam G (2000). Scylloinositol in post-mortem brain of bipolar, unipolar and schizophrenic patients. J Neural Transm 107: 603-607.
38. Sjoholt G, Gulbrandsen AK, Lovlie R, Berle J, Molven A, Steen VM (2000). A human myo-inositol monophosphatase gene (IMPA2) localized in a putative susceptibility region for bipolar disorder on chromosome 18p11.2: genomic structure and polymorphism screening in manic-depressive patients. Mol Psychiatry 5: 172-180.
39. van Calker D, Belmaker RH (2000). The high affinity inositol transport system - implications for the pathophysiology and treatment of bipolar disorder: an editorial. Bipolar Disord 2: 102-107.
40. Yoshikawa T, Padigaru M, Karkera JD, Sharma M, Berrettini WH, Esterling LE et al (2000). Genomic structure and novel variants of myo-inositol monophosphatase 2 (IMPA2). Mol Psychiatry 5: 165-171.
41. Yoshikawa T, Turner G, Esterling LE, Sanders AR, Detera-Wadleigh SD (1997). A novel human myo-inositol monophosphatase gene, IMP.18p, maps to a susceptibility region for bipolar disorder. Mol Psychiatry 2: 393-397.
42. Youngs RM, Chu MS, Meloni EG, Naydenov A, Carlezon Jr WA, Konradi C (2006). Lithium administration to preadolescent rats causes long-lasting increases in anxiety-like behavior and has molecular consequences. J Neurosci 26: 6031-6039.
43. Zambrowicz BP, Friedrich GA (1998). Comprehensive mammalian genetics: history and future prospects of gene trapping in the mouse. Int J Dev Biol 42: 1025-1036.